

From: Morris, Nevitt
To: paul.gil@sparktx.com; jim.wang@sparktx.com
Cc: Morris, Nevitt
Subject: BLA 125610 Spark / Lot Release Specifications Information Request
Date: Friday, November 24, 2017 12:30:22 PM
Attachments: image001.png

(File Attachment comment)
Hi Paul and Jim:

Your revised Lot Release Specifications are acceptable. Please submit a revised Lot Release Protocol based on the specifications agreed by FDA to your BLA, as soon as possible.

Thanks and please acknowledge receipt of this email request.

Nevitt

Nevitt Morris

Nevitt
Morris,
RN,
BSN,
BS
Consumer
Safety
Officer
Office
of
Tissues
and
Advanced
Therapies
Center
for
Biologics
Evaluation
and
Research
(CBER)

U.S.
Food
and
Drug
Administration
Building
71,
Room

4207
10903
New
Hampshire
Avenue
Silver
Spring,
MD 20993
Phone: (240)
402-8269
Fax: (301)
595-1303
Nevitt.Morris@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS
ADDRESSED
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND
PROTECTED
FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person
authorized to deliver
the document to the addressee, you are hereby notified that any review,
disclosure,
dissemination, copying, or other action based on the content of this
communication is not
authorized. If you have received this document in error, please
immediately notify the sender
immediately by e-mail or phone.
(Unsigned signature field (Click to sign)) Signature field is unsigned

